{"schema_version":"secwatch.filing_event.v1","accession":"0001559053-23-000014","form_type":"8-K","ticker":"PRTA","cik":"0001559053","company_name":"PROTHENA CORP PUBLIC LTD CO","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.382126+00:00","generated_at":"2026-06-15T21:52:09.916453+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Prothena Q1 net loss widens to $46.9M; pipeline progress with PRX012, PRX005 data","bullets":["Net loss of $46.9M ($0.89 per share) vs $36.3M ($0.78) in Q1 2022; revenue $2.2M from BMS collaboration.","Cash position $688.4M; FY 2023 guidance: net cash used $213-229M, year-end cash ~$512M.","PRX012 preclinical data at AD/PD showed 20-fold higher affinity vs lecanemab; PRX005 Phase 1 SAD met safety objective.","Key milestones: PRX012 topline data year-end 2023; birtamimab Phase 3 AFFIRM-AL topline in 2024.","R&D expenses rose to $44.8M from $27.3M driven by clinical trial costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001559053-23-000014","json":"https://secwatch.observer/filing/0001559053-23-000014.json","markdown":"https://secwatch.observer/filing/0001559053-23-000014.md","text":"https://secwatch.observer/filing/0001559053-23-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000014/0001559053-23-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000014/prta-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:52:09.916453+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"94fc6157b32e1b6ed3b83441333033c449cde012","claim":"PROTHENA CORP PUBLIC LTD CO reported first quarter of 2023 results: net income $46.9 million.","evidence_excerpt":"For the first quarter of 2023, Prothena reported net loss of $46.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1559053/000155905323000014/0001559053-23-000014-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2023"},{"label":"Net income","value":"$46.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}